Iris Medicine key facts
as of Oct 2026- Developer of a ribonucleic acid therapeutics platform designed to treat genetic diseases.
- Iris Medicine is valued at approximately $4.4M as of Oct 2026 (last reported valuation).
- It has raised $400K; the latest was Later Stage VC in Jan 2025.
- Notable investors include Venrock, Altitude Life Science Ventures, Berkeley Catalyst Fund Management, PsyMed Ventures, UCB Ventures.
- Status: Privately Held (backing).
Iris Medicine's last reported valuation, May 2020. Nothing priced has surfaced since.
- ·Watch Iris Medicine: the Monday email on marks, rounds and moves
Iris Medicine funding rounds
No funding rounds for Iris Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Iris Medicine valuation
Iris Medicine's last reported valuation was $4.4 million in May 2020. No priced round, secondary trade or fund mark has surfaced since.
Iris Medicine investors
5 investors are on record for Iris Medicine, including Venrock, Altitude Life Science Ventures, Berkeley Catalyst Fund Management and PsyMed Ventures.
About Iris Medicine
Developer of a ribonucleic acid therapeutics platform designed to treat genetic diseases. The company's platform leverages the cooperativity inherent in the RNAi machinery to selectively modulate ribonucleic acid transcripts harboring expanded, pathologic repeat sequences, enabling medical professionals to streamline the treatment of neurological diseases.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2019
- Employees
- 11
- Website
- irismedicine.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.